This study investigates an investigational oncolytic virus therapy for advanced solid tumors. Oncolytic viruses are designed to infect and destroy cancer cells and may stimulate the immune system to fight the tumor.
The purpose of this study is to evaluate the safety and tolerability of the investigational therapy and to determine the highest dose that can be safely given. Researchers will also observe how the treatment behaves in the body and its impact on the immune system.
- Who can participate: Adults aged 18 and older with advanced solid tumors that have progressed despite standard therapy may be eligible. Participants must have measurable disease, adequate organ function, ECOG performance status, adequate bone marrow function, and be able to provide informed consent.
- Study details: Participants will receive a single intravenous infusion of the investigational therapy and be monitored for side effects. The study will evaluate how the treatment affects the body and immune response.
How understandable was the trial content above?
Hard to understand
Easy to understand